Results 131 to 140 of about 36,830 (259)

Divergent Paths: A Comprehensive Review of Mechanisms and Clinical Implications in Atopic Dermatitis and Psoriasis

Allergy, EarlyView.
ABSTRACT Atopic dermatitis and psoriasis are two common cutaneous chronic inflammatory diseases. Although they share similar immunological mechanisms, their clinical implications in the patient are different. This review compares both diseases from different points of view such as genetics, natural history, triggers of disease, and skin barrier defects
Tali Czarnowicki, Kazunari Sugita, Zenas Yiu, Sandra Díez‐Ribas, Irene Garcia‐Jimenez, Emma Guttman‐Yassky, Luis F. Santamaria‐Babí   +6 more
wiley   +1 more source

Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. [PDF]

RMD Open, 2021
Stouten V, Pazmino S, Verschueren P, Mamouris P, Westhovens R, de Vlam K, Bertrand D, Van der Elst K, Vaes B, De Cock D.   +9 more
europepmc   +1 more source

PSORIATIC ARTHRITIS [PDF]

Rheumatology, 1984
openaire   +2 more sources

Safety of Venom Immunotherapy in Pregnancy: A Multicentre Study

Allergy, EarlyView.
Venom immunotherapy (VIT) during pregnancy, when maintenance dose is well tolerated, can be continued. No increased risk of adverse effects to VIT or safety concerns for the pregnancy or the newborns were observed. No decreased efficacy of VIT, in case of re‐stings, was reported.
Matteo Martini, Giovanna Sfriso, Valerio Pravettoni, Marina Mauro, Donatella Preziosi, Francesca Vettorato, Giuseppe Lucchini, Mauro Pagani, Iuliana Badiu, Maria Pia Dolcher, Francesco Gaeta, Pietro Galati, Elisa Meucci, Elide Pastorello, Vincenzo Patella, Stefano Pucci, Chiara Roncallo, Eleonora Savi, Livio Simioni, Maria Beatrice Bilò, Patrizia Bonadonna   +20 more
wiley   +1 more source

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. [PDF]

RMD Open, 2021
Burmester GR, Nash P, Sands BE, Papp K, Stockert L, Jones TV, Tan H, Madsen A, Valdez H, Cohen SB.   +9 more
europepmc   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara, Tanja Tran, Sandeep Kiri, Romy Bley, Kathrin Schlüter, Claudia Grellmann, Sima Melnik, Sylke Schneider‐Burrus   +7 more
wiley   +1 more source

The comparative prevalence of comorbidities across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. [PDF]

Rheumatol Adv Pract
Williams JC, Southworth J, Rogers K, Zhao SS.   +3 more
europepmc   +1 more source

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis, Sandra Philipp, Thomas Mosch, Björn Fritz, Robert Sabat   +4 more
wiley   +1 more source

Maternal and neonatal outcomes in pregnancies with rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: a comparative study. [PDF]

BMC Rheumatol
Al Emadi S, Satti E, Cackamvalli P, Hadwan N.   +3 more
europepmc   +1 more source

PeakPASI as a marker of maximum psoriasis severity: a single‐center, cross‐sectional retrospective and questionnaire‐based study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The Psoriasis Area and Severity Index (PASI) is the standard measure for psoriasis severity but reflects only a single time point and may underestimate long‐term disease burden. To assess whether the highest‐ever recorded PASI (PeakPASI) can serve as a marker of historical disease severity and correlate with treatment burden and ...
Simran Wilkhoo, Stefanie Ziehfreund, Enya Müller, Hanna Wecker, Stefanie Eyerich, Tilo Biedermann, Alexander Zink   +6 more
wiley   +1 more source